Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

NCT ID: NCT00102908

Last Updated: 2008-09-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-05-31
• Study Completion Date: 2009-12-31

Brief Summary

Bisphosphonates are a type of drug used to prevent and treat bone loss. The purpose of this study is to determine if zoledronate, an investigational bisphosphonate, can improve bone mineral density (BMD) in HIV-infected adults.

Study hypothesis: Zoledronate will reduce bone resorption in HIV-infected persons with osteopenia.

Detailed Description

Decreased BMD and bone loss is estimated to affect up to 67.5% of the HIV-infected population. HIV-associated bone loss may be a result of antiretroviral treatment (ART), but can also be caused by the infection itself. To date, treatment for this bone loss has not been established. Before prescribing drugs to treat bone loss, physicians must take into account patients' already demanding ART schedules and potential nonadherence. This study will evaluate the efficacy of a single IV dose of zoledronate, an investigational bisphosphonate, in treating HIV-associated bone loss.

This study will last 1 year. Participants will be randomly assigned to receive zoledronate or placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis. There will be 7 study visits: at screening, study entry, Week 2, and Months 3, 6, 9, and 12. Blood collection will occur at all visits. Medical history, a physical exam, a dual-energy x-ray absorptiometry (DEXA) scan to measure bone density, and a nutrition evaluation will occur at selected visits.

Conditions

HIV Infections; Osteopenia; Osteoporosis

Keywords

Bone Metabolism; Osteopenia; Osteoporosis; Treatment Experienced

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis

Group Type: EXPERIMENTAL

Zoledronate

Intervention Type: DRUG

Zoledronate infusion

2

Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis

Group Type: PLACEBO_COMPARATOR

Zoledronate placebo

Intervention Type: DRUG

Zoledronate placebo infusion

Interventions

Zoledronate

Zoledronate infusion

Intervention Type: DRUG

Zoledronate placebo

Zoledronate placebo infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• HIV-infected
• On stable antiretroviral regimen for at least 3 months
• Able to walk
• Lumbar spine or total hip BMD T-score at least 1.5 SD and no more than 3.5 SD below the mean BMD
• No prevalent fractures at entry OR 1 prevalent vertebral fracture that has been asymptomatic during the last 2 years prior to study entry
• HIV viral load of less than 5000 copies/ml within the 2 months prior to study entry
• CD4 count of more than 100 cells/mm3 within the 2 months prior to study entry
• Willing to use acceptable forms of contraception during the study period and for 6 months after study completion. Participants who are female and postmenopausal will be required to take hormone replacement therapy during this study.

Exclusion Criteria

• Prior treatment with bisphosphonates or fluoride
• Use of supraphysiologic systemic estrogen/androgen therapy or corticosteroid therapy within the 3 months prior to study entry. Participants who have taken hormone replacement therapy are not excluded.
• Significant liver or kidney disease
• Hemoglobin less than 8 g/dL
• Serum calcium less than 8 mg/dL
• Laboratory evidence of low levels of estrogens or androgens
• Laboratory evidence of overactive parathyroid glands
• History of thyroid, parathyroid, or other endocrinologic disorder known to affect bone
• Current use of any therapy known to affect bone
• Current or history of cancer or chemotherapy
• Current or history of radiotherapy to the jaw
• Current osteomyelitis of the jaw or ongoing dental infection
• Recent tooth extraction or major dental procedure within 3 weeks of study entry
• Pregnancy or breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

University of California, San Diego

Principal Investigators

Jeannie S. Huang, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Locations

University of California, San Diego

San Diego, California, United States

Countries

United States

Other Identifiers

1R21AI058756-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R21AI058756-01

Identifier Type: NIH

Identifier Source: org_study_id

View Link